Elevate your intimacy with sexual health protocols
52%
the average amount of men that suffer from ED between the ages of 40-70. Approximately 40% of men experience some degree of ED, including men under the age of 40 (26%)
PT-141
A synthetic melanocortin receptor agonist that primarily targets melanocortin receptors, studied for its role in modulating sexual arousal pathways and neurobehavioral responses independent of vascular mechanisms. Premium Research Peptide.
$189.99
Dosage
Fast Free Shipping
Shipment Protection
10mg
Size
HPLC≥99%
Purity
Lyophilized Powder
Form
Peptide products offered through this platform are provided for informational and research purposes or are made available only pursuant to evaluation and authorization by a licensed healthcare provider, where applicable. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Use of any peptide product should be conducted under appropriate professional supervision. All content provided is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before beginning any new wellness or medical program.
40%
roughly 10% of women suffer from Hypoactive Sexual Desire Disorder (HSDD) and studies indicate that up to 40% of women may experience it at some point in their lives
A peptide designed for true arousal.
Desire begins in the brain. PT-141 is designed to activate pathways involved in sexual desire and arousal, helping support the natural process that comes before the physical response. Unlike treatments that focus primarily on blood flow, PT-141 works centrally to help reignite sexual interest and intimacy.
Men & Women
the active ingredient has been studied in both
45 Min.
typical onset, effects may last several hours
Neurology
works on desire and arousal, not blood flow.
99.8% Purity
lab-tested in a US-licensed pharmacy
Bremelanotide’s terminal half-life is about 2.7 hours. Onset and duration of effect vary by person. The 99.8% purity figure is from Neuera product testing. The Neuera compounded product has not been reviewed or approved by the FDA. Individual results vary.
PT-141
PT-141 is a heptapeptide derivative of Melanotan II, engineered to selectively activate melanocortin receptors (MC3R and MC4R). Research has investigated these receptors for their involvement in central arousal pathways, energy balance mechanisms, and vascular tone regulation.
The cyclic structure of PT-141 has been studied for enhanced stability and receptor selectivity characteristics compared to native α-MSH fragments, making it a useful tool in melanocortin receptor research.
Formula:
CAS Number:
Molecular Weight:
Research Focus:
C50H68N14O10
189691-06-3
1025.2 g/mol
Melanocortin receptors, CNS pathways
PT-141 is administered subcutaneously in research settings and is currently under investigation for CNS melanocortin pathways, vascular modulation mechanisms, and central arousal research in laboratory studies.
Sources: National Institute of Health (nih.gov), ResearchGate, Lippincott (Obstetrics & Gynecology)
Neuera™ is an independent platform and is not affiliated with, endorsed by, or sponsored by the National Institutes of Health (NIH) or any other government organization. Product names, logos, brands, and other trademarks featured or referred to within this website are the property of their respective trademark holders. These names and logos are used strictly for identification, educational, and source-referencing purposes.